Trial Profile
Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary) ; Caspofungin
- Indications Invasive candidiasis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 23 Apr 2021 Results Results of post hoc pooled analysis from NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; evaluating patient level efficacy and safety data of anidulafungin, published in the Clinical Drug Investigation
- 17 Apr 2014 New trial record
- 23 Jul 2012 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.